Anorexia nervosa: Manifestations and management for the gastroenterologist

American Journal of Gastroenterology

Volumn 97, Issue 2, 2002, Pages 255-269

  Chial, Heather J ^a   McAlpine, Donald E ^a   Camilleri, Michael ^a,b  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; BETHANECHOL; BUSPIRONE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DOMPERIDONE; DOPAMINE; FLUOXETINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HOMOVANILLIC ACID; LEPTIN; METOCLOPRAMIDE; NEUROPEPTIDE Y; OLANZAPINE; PROKINETIC AGENT; PROLACTIN; RECOMBINANT GROWTH HORMONE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN;

ANOREXIA NERVOSA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COLON MOTILITY; COMORBIDITY; COUNSELING; ESOPHAGUS DISEASE; FEMALE; GENETIC ASSOCIATION; HUMAN; HUNGER; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROENDOCRINOLOGY; NEUROLOGICAL COMPLICATION; NUTRITION; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; REFEEDING; REVIEW; SATIETY; SEX DIFFERENCE; STOMACH EMPTYING; SYNDROME;

ANOREXIA NERVOSA; COMBINED MODALITY THERAPY; FEMALE; GASTROENTEROLOGY; HUMANS; MALE; PROGNOSIS; PSYCHOLOGICAL TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0036177034     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04014-X     Document Type: Review

References (198)

1. The rumination syndrome: Clinical features rather than manometric diagnosis
2. The rumination syndrome: Clinical and manometric profile, therapy, and long-term outcome
3. Rumination syndrome
4. Eating disorders revisited. I: Anorexia nervosa
5. Eating disorders
6. Initial assessment and early treatment options for anorexia nervosa and bulimia nervosa
7. Anorexia nervosa. No evidence of an increase
8. Epidemiology of the eating disorders
9. Epidemiology of anorexia nervosa
10. Medical complications occurring in adolescents with anorexia nervosa
11. Anorexia nervosa rates - Conclusions for the wrong reasons
12. Onset of adolescent eating disorders: Population based cohort study over 3 years
13. A review of anorexia nervosa and bulimia nervosa
14. Increasing incidence of anorexia nervosa in the female population of northeast Scotland
15. The ups and downs of anorexia nervosa
16. Anorexia nervosa and bulimia nervosa in children and adolescents: A review of the past 10 years
17. Secular trends in the incidence of anorexia nervosa: Integrative review of population-based studies
18. Issues in mapping genes for eating disorders
19. Anorexia nervosa and anorexic-like syndromes in a population-based female twin sample
20. Genetic and environmental influences on anorexia nervosa syndromes in a population-based twin sample
21. Twin studies and the etiology of eating disorders
22. Behavior genetics and eating disorders
23. Genetic factors in anorexia nervosa
24. Controlled family study of anorexia nervosa and bulimia nervosa: Evidence of shared liability and transmission of partial syndromes
25. Twin studies of eating disorders: A review
26. 5-HT2A promoter polymorphism in anorexia nervosa
27. 5-HT2A promoter polymorphism-1438G/A, anorexia nervosa, and obsessive-compulsive disorder
28. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa
29. New directions in treatment research of anorexia and bulimia nervosa
30. Lack of association between 5-HT2A gene promoter polymorphism and susceptibility to anorexia nervosa
31. 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity
32. 5-HT2A receptor gene polymorphisms in anorexia nervosa and bulimia nervosa
33. Further lack of association between the 5-HT2A gene promoter polymorphism and susceptibility to eating disorders and a meta-analysis pertaining to anorexia nervosa
34. Analysis of the serotonin transporter gene linked polymorphism (5-HT-TLPR) in anorexia nervosa
35. No coding variant of the tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism
36. No evidence for involvement of the leptin gene in anorexia nervosa, bulimia nervosa, underweight or early onset extreme obesity: Identification of two novel mutations in the coding sequence and a novel polymorphism in the leptin gene linked upstream region
37. No evidence for involvement of polymorphisms of the dopamine D4 receptor gene in anorexia nervosa, underweight, and obesity
38. A search for susceptibility loci for anorexia nervosa: Methods and sample description
39. Six-year course and outcome of anorexia nervosa
40. Psychiatric comorbidity in patients with eating disorders
41. Anorexia nervosa in 51 Swedish adolescents: Premorbid problems and comorbidity
42. Psychiatric comorbidity in treatment-seeking anorexics and bulimics
43. Ten-year follow-up of adolescent-onset anorexia nervosa: Personality disorders
44. Clinical characteristics in patients with anorexia nervosa and obsessive-compulsive disorder
45. Eating disorders in female inpatients with versus without substance use disorders
46. Histories of childhood trauma and complex post-traumatic sequelae in women with eating disorders
47. The childhood and family background of women with clinical eating disorders: A comparison with women with major depression and women without psychiatric disorder
48. Marked transaminase elevation in anorexia nervosa
49. Lipid levels in anorexia nervosa
50. Treatment of anorexia nervosa
51. Medical complications of anorexia nervosa and bulimia nervosa
52. Eating disorders. Guide to medical evaluation and complications
53. Cardiac abnormalities in young women with anorexia nervosa
54. Heart risk associated with weight loss in anorexia nervosa and eating disorders: Electrocardiographic changes during the early phase of refeeding
55. QT interval in anorexia nervosa
56. Medical complications of anorexia nervosa
57. Neuroimaging in anorexia nervosa
58. A case of marked cerebellar atrophy in a woman with anorexia nervosa and cerebral atrophy and a review of the literature
59. Computed tomography of anorexia nervosa
60. Neuropsychological consequences of extreme weight loss and dietary restriction in patients with anorexia nervosa
61. Estrogen replacement therapy in the management of osteopenia related to eating disorders
62. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea
63. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa
64. The effects of anorexia nervosa on bone metabolism in female adolescents
65. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa
66. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission
67. Osteoporosis in women with anorexia nervosa
68. Eating disorders
69. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa
70. Decreased bone density in adolescent girls with anorexia nervosa
71. Long-term fracture risk among women with anorexia nervosa: A population-based cohort study
72. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa
73. Effect of hormone replacement therapy on bone density in a patient with severe osteoporosis caused by anorexia nervosa
74. From malnutrition to refeeding during anorexia nervosa
75. Mortality in eating disorders: A descriptive study
76. Mortality in anorexia nervosa in Denmark during the period 1970-1987
77. Standardized mortality in eating disorders - A quantitative summary of previously published and new evidence
78. Oesophageal and gastric motility disorders in patients categorised as having primary anorexia nervosa
79. Gastric, colonic, and esophageal motility in anorexia. Relationship with symptoms, psychopathological distress and results of treatment
80. Abnormal gastric emptying in primary anorexia nervosa
81. Altered gastric emptying and secretion in primary anorexia nervosa
82. Gastric electromechanical and neurohormonal function in anorexia nervosa
83. Definition of a gastric emptying abnormality in patients with anorexia nervosa
84. Metoclopramide-induced gastric emptying in patients with anorexia nervosa
85. Effect of bethanechol on gastric functions in primary anorexia nervosa
86. Intravenous cisapride accelerates delayed gastric emptying and increases antral contraction amplitude in patients with primary anorexia nervosa
87. Gastric hyposensitivity and large gastric capacity in patients with bulimia nervosa, but not in patients with anorexia nervosa
88. Temporal patterns of hunger and fullness ratings and related cognitions in anorexia and bulimia
89. Small bowel transit time measured by hydrogen breath test in patients with anorexia nervosa
90. Delayed gastrointestinal transit times in anorexia nervosa and bulimia nervosa
91. Colonic and anorectal function in constipated patients with anorexia nervosa
92. Anorectal dysfunction in constipated women with anorexia nervosa
93. Psychological disorders in patients with evacuation disorders and constipation in a tertiary practice
94. Functional gastrointestinal disorders and eating disorders. Relevance of the association in clinical management
95. Acute gastric dilatation in anorexia nervosa
96. Acute dilatation of the stomach in a patient with anorexia nervosa
97. Acute dilatation and spontaneous rupture of the stomach
98. Acute pancreatitis and gastric dilatation in a patient with anorexia nervosa
99. Anorexia nervosa and necrotizing colitis
100. Anorexia nervosa: Death from complications of ruptured gastric ulcer
101. Central and peripheral ACTH and cortisol levels in anorexia nervosa and bulimia
102. The hypothalamic-pituitary-adrenal axis in anorexia nervosa
103. Influence of weight loss on the dexamethasone suppression test
104. A review of endocrine changes in anorexia nervosa
105. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa
106. Functional impairment of hypothalamic corticotropin-releasing factor neurons with immunotargeted toxins enhances food intake induced by neuropeptide Y
107. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats
108. A comparative and longitudinal study on endocrine changes related to ovarian function in patients with anorexia nervosa
109. Hypothalamic-pituitary-gonadal function in anorexia nervosa and bulimia
110. Role of leptin in fat regulation
111. Role of leptin in the neuroendocrine response to fasting
112. The role of the central nervous system in the psychoneuroendocrine disturbances of anorexia and bulimia nervosa
113. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa
114. The reproductive endocrine consequences of anorexia nervosa
115. Hypothalamic-endocrine dysfunction in anorexia nervosa
116. Clinical conference. Anorexia nervosa
117. Sex differences and similarities of hormonal alterations in patients with anorexia nervosa
118. Reversible weight related increase in plasma testosterone during treatment of male and female patients with anorexia nervosa
119. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass
120. Decreased thyroidal triiodothyronine secretion in patients with anorexia nervosa: Influence of weight recovery
121. Hypothalamic-pituitary-thyroidal dysfunctions in anorexia nervosa
122. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: Indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis
123. Spontaneous nocturnal growth hormone secretion in anorexia nervosa
124. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: A comparison with normal subjects and patients with hypopituitarism or critical illness
125. Neuroendocrinological response to standardized mixed meal in female anorectic patients during active and refeeding phases
126. Abnormalities in CNS monoamine metabolism in anorexia nervosa
127. Altered dopamine activity after recovery from restricting-type anorexia nervosa
128. Central and peripheral noradrenalin regulation in eating disorders
129. State-related changes in norepinephrine regulation in anorexia nervosa
130. Neuropeptide Y: A central regulator of energy homeostasis
131. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients
132. Expression of leptin and leptin receptor isoforms in the human stomach
133. Leptin is a growth factor for colonic epithelial cells
134. Leptin: Physiology and pathophysiology
135. Body fat, caloric intake, and plasma leptin levels in women with anorexia nervosa
136. Leptin in relation to resumption of menses in women with anorexia nervosa
137. Circulating leptin in patients with anorexia nervosa, bulimia nervosa or binge-eating disorder: Relationship to body weight, eating patterns, psychopathology and endocrine changes
138. Role of leptin in reproduction
139. Serotonin: A mediator of the brain-gut connection
140. Research update on serotonin function in bulimia nervosa and anorexia nervosa
141. Serotonin and appetite
142. Serotonin manipulations and the structure of feeding behaviour
143. Serotonin and the biology of feeding
144. Serotonin, eating behavior, and fat intake
145. Hypothalamic serotonin: Pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action
146. Hypothalamic serotonin in the control of meal patterns and macronutrient selection
147. Separate systems for serotonin and leptin in appetite control
148. Hypothalamic serotonin in control of eating behavior, meal size, and body weight
149. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat
150. The role of putative 5-HT1A and 5-HT1B receptors in the control of feeding in rats
151. Serotonin and appetite
152. 5-HT1B agonists induce anorexia at a postsynaptic site
153. Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia
154. Anorexia nervosa, obsessional behavior, and serotonin
155. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa
156. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?
157. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa
158. Psychological treatment for eating disorders
159. Practice guidelines for the treatment of patients with eating disorders
160. The long-term course of severe anorexia nervosa in adolescents: Survival analysis of recovery, relapse, and outcome predictors over 10-15 years in a prospective study
161. Impact of hospitalisation on the outcome of adolescent anorexia nervosa
162. Predictors of success or failure of transition to day hospital treatment for inpatients with anorexia nervosa
163. Psychosocial and pharmacological treatment of eating disorders: A review of research findings
164. Medications in the treatment of eating disorders
165. Does early intervention improve the prognosis in anorexia nervosa? A systematic review of the treatment-outcome literature
166. Nutritional management of anorexia
167. Nutritional management of eating disorders
168. Hypophosphatemia secondary to oral refeeding in anorexia nervosa
169. The refeeding syndrome: A review
170. Cognitive behavior therapy for eating disorders: Progress and problems
171. Evaluation of family treatments in anorexia nervosa: A pilot study
172. I. An evaluation of family therapy in anorexia nervosa and bulimia nervosa
173. The use of selective serotonin reuptake inhibitors in eating disorders
174. Selective serotonin reuptake inhibitors in anorexia
175. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline
176. Amitriptyline in the treatment of anorexia nervosa: A double-blind, placebo-controlled study
177. Hunger, food intake and weight: The impact of clomipramine on a refeeding anorexia nervosa population
178. Clomipramine and "drive" in people with anorexia nervosa: An in-patient study
179. Anorexia nervosa: Treatment with olanzapine
180. Case reports of olanzapine treatment of anorexia nervosa
181. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients
182. Delayed gastric emptying and improvement with domperidone in a patient with anorexia nervosa
183. A placebo-controlled crossover study of oral clonidine in acute anorexia nervosa
184. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans
185. Males with eating disorders: Challenges for treatment and research
186. Psychiatric comorbidity of eating disorders in men: A national study of hospitalized veterans
187. Eating disorders in a national sample of hospitalized female and male veterans: Detection rates and psychiatric comorbidity
188. Eating disorders in males: A report on 135 patients
189. Adolescent boys and anorexia nervosa
190. Clinical presentation of anorexia nervosa in males: 24 New cases
191. More males seek treatment for eating disorders
192. Neuropeptide abnormalities in anorexia nervosa
193. No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: An historical case-control study
194. Does fluoxetine augment the inpatient treatment of anorexia nervosa?
195. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls
196. An open trial of fluoxetine in patients with anorexia nervosa
197. Fluoxetine treatment of anorexia nervosa: An open clinical trial